Home Buprenorphine/Naloxone Induction in Primary Care

  • Joshua D. Lee
  • Ellie Grossman
  • Danae DiRocco
  • Marc N. Gourevitch
Original Article

ABSTRACT

BACKGROUND

Buprenorphine can be used for the treatment of opioid dependence in primary care settings. National guidelines recommend directly observed initial dosing followed by multiple in-clinic visits during the induction week. We offered buprenorphine treatment at a public hospital primary care clinic using a home, unobserved induction protocol.

METHODS

Participants were opioid-dependent adults eligible for office-based buprenorphine treatment. The initial physician visit included assessment, education, induction telephone support instructions, an illustrated home induction pamphlet, and a 1-week buprenorphine/naloxone prescription. Patients initiated dosing off-site at a later time. Follow-up with urine toxicology testing occurred at day 7 and thereafter at varying intervals. Primary outcomes were treatment status at week 1 and induction-related events: severe precipitated withdrawal, other buprenorphine-prompted withdrawal symptoms, prolonged unrelieved withdrawal, and serious adverse events (SAEs).

RESULTS

Patients (N = 103) were predominantly heroin users (68%), but also prescription opioid misusers (18%) and methadone maintenance patients (14%). At the end of week 1, 73% were retained, 17% provided induction data but did not return to the clinic, and 11% were lost to follow-up with no induction data available. No cases of severe precipitated withdrawal and no SAEs were observed. Five cases (5%) of mild-to-moderate buprenorphine-prompted withdrawal and eight cases of prolonged unrelieved withdrawal symptoms (8% overall, 21% of methadone-to-buprenorphine inductions) were reported. Buprenorphine-prompted withdrawal and prolonged unrelieved withdrawal symptoms were not associated with treatment status at week 1.

CONCLUSIONS

Home buprenorphine induction was feasible and appeared safe. Induction complications occurred at expected rates and were not associated with short-term treatment drop-out.

Supplementary material

11606_2008_866_MOESM1_ESM.pdf (723 kb)
Online Appendix“Burpenorphine – Beginning Treatment” (please see attached PDF) (PDF 544 KB)

References

  1. 1.
    Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.Google Scholar
  2. 2.
    Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opiate dependence. Am J Psychiatry. 2004;151(7):1025–30.Google Scholar
  3. 3.
    Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;16(2):CD002207.Google Scholar
  5. 5.
    Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. SAMHSA Evaluation of the Impact of the DATA Waiver Program. http://buprenorphine.samsha.gov/, accessed May 12, 2008.
  6. 6.
    Kuehn B. Office-based treatment of opioid addiction achieving goals. JAMA. 2005;294(7):784–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Sullivan LE, Chawarski M, O’Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79(1):113–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.CrossRefPubMedGoogle Scholar
  11. 11.
    Netherland J, Botsko M, Egan J, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. In Press, available online 20 Aug 2008.Google Scholar
  12. 12.
    American Academy of Addiction Psychiatry. Buprenorphine in the treatment of opioid dependence. http://training.aaap.org/, accessed Nov. 14, 2008.
  13. 13.
    American Society of Addiction Medicine, Clinical Tools, Inc. Online buprenorphine training. http://buprenorphineCME.com, accessed Nov. 14, 2008.
  14. 14.
    Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22(2):171–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Paasche-Orlow MK, Schillinger D, Greene SM, Wagner EH. How health care systems can begin to address the challenge of limited literacy. J Gen Intern Med. 2006;21(8):884–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alc Dep. 1990;26(1):19–28.CrossRefGoogle Scholar
  19. 19.
    Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine for opioid dependence. JAMA. 1992;267(20):2750–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004;13(S1):S42–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med. 2007;1(2):104–10.CrossRefGoogle Scholar
  24. 24.
    Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500–6.PubMedGoogle Scholar
  25. 25.
    Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274:361–72.PubMedGoogle Scholar
  26. 26.
    Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59–77.CrossRefPubMedGoogle Scholar
  27. 27.
    Magura S, Lee S, Salsitz E, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26(2):13–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Soyka M, Zingg C, Koler G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psych. 2005;162(2):340–9.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  • Joshua D. Lee
    • 1
    • 2
  • Ellie Grossman
    • 1
  • Danae DiRocco
    • 1
  • Marc N. Gourevitch
    • 1
  1. 1.New York University School of MedicineNew YorkUSA
  2. 2.New YorkUSA

Personalised recommendations